Abstract |
Interferon beta-1b (IFNbeta-1b) is effective in reducing the frequency of exacerbations in patients with relapsing-remitting multiple sclerosis (RRMS). Recently, a study suggested that treatment with IFNbeta-1b may place MS patients at risk of exacerbations by increasing interferon-gamma (IFNgamma)-secreting cells in the blood early after onset of treatment. We conducted a retrospective study in 192 RRMS patients treated with IFNbeta-1b. We did not observe an increase in the frequency of exacerbations early after the onset of treatment and suggest that the IFNgamma-secreting cell surge linked to the onset of treatment with IFNbeta-1b may not be clinically significant.
|
Authors | O A Khan, J R Hebel |
Journal | Annals of neurology
(Ann Neurol)
Vol. 44
Issue 1
Pg. 138-9
(Jul 1998)
ISSN: 0364-5134 [Print] United States |
PMID | 9667604
(Publication Type: Journal Article)
|
Chemical References |
- Glucocorticoids
- Neuroprotective Agents
- Recombinant Proteins
- Interferon beta-1b
- Interferon-beta
- Prednisone
- Methylprednisolone
- Interferon beta-1a
|
Topics |
- Administration, Oral
- Adult
- Case-Control Studies
- Female
- Glucocorticoids
(administration & dosage)
- Humans
- Incidence
- Injections, Intravenous
- Interferon beta-1a
- Interferon beta-1b
- Interferon-beta
(adverse effects, therapeutic use)
- Male
- Methylprednisolone
(administration & dosage)
- Middle Aged
- Multiple Sclerosis
(therapy)
- Nervous System Diseases
(epidemiology, etiology, prevention & control)
- Neuroprotective Agents
(administration & dosage)
- Prednisone
(administration & dosage)
- Recombinant Proteins
(adverse effects, therapeutic use)
- Recurrence
- Retrospective Studies
|